Heart Test Laboratories Funding & Investors

HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease. WHO IS HEARTSCIENCES: • Incorporated in 2007, HeartSciences (formerly known as Heart Test Laboratories) is a privately held medical device company located in the Dallas-Fort Worth metroplex, the largest economic area in the Southern United States • For more than a decade, HeartSciences has been dedicated to the development of accurate, affordable screening tools for the early detection of heart disease. • To date, HeartSciences has invested more than $30M in research and development to bring innovation to electrocardiography (ECG/EKG) medical devices, an industry that has not experienced disruptive technological advancement in decades - until now. • HeartSciences is led by CEO Mark Hilz and Chairman Andrew Simpson, seasoned entrepreneurs with years of combined experience building successful start-up companies and growing firms in both the technology and financial sectors.